Otsuka Pharmaceutical Development & Commercialization, Inc.

This study tested whether adding aripiprazole to lamotrigine helps people with bipolar I disorder avoid future manic or mixed episodes. Over 1,100 adults took part for up to a year. The goal was to see if the combination kept mood stable longer than lamotrigine alone.

This study looked at how well a new drug, SEP-363856, works and how safe it is for people with schizophrenia who switch from their current antipsychotic medication. About 100 clinically stable adults took part over 8 weeks. The main goal was to see how many stopped the study due …

This study tested a new oral drug called JNT-517 in healthy volunteers and people with phenylketonuria (PKU), a genetic condition that causes harmful buildup of phenylalanine. The main goals were to check safety, how the body processes the drug, and its effect on phenylalanine le…

This study looked at the long-term safety of the drug brexpiprazole in teenagers aged 13 to 17 with schizophrenia. Researchers monitored side effects and how well the teens tolerated the medication over time. The goal was to understand if brexpiprazole is a safe maintenance treat…

This study tested a new drug called VIS649 in 155 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Participants received either VIS649 or a placebo, and researchers monitored side …

This early-stage study tested a new drug, VIS171, in 61 people to see if it is safe. First, healthy volunteers received a single dose. Then, people with autoimmune diseases received multiple doses. The main goal was to check for side effects and how the drug affects immune cells.…

This study tested an experimental drug called JNT-517 in 14 teenagers with phenylketonuria (PKU), a genetic condition that causes harmful buildup of an amino acid. Participants took either the drug or a placebo twice daily for 28 days to check safety and how the body processes th…

This study looked at whether a second stem cell transplant, using a personalized dose of busulfan plus bortezomib, could help control multiple myeloma that had come back after a first transplant. Thirty adults aged 18 to 75 took part. The goal was to see how many patients had the…

This study tested a new drug called SEP-363856 to see if it is safe for people with schizophrenia to take over a long period. About 305 adults aged 18 to 65 with schizophrenia took part for up to 57 weeks. The main goal was to track any side effects or serious health issues that …

This study looked at the long-term safety of a once-daily medication called centanafadine for children and teens (ages 4 to 17) with ADHD. About 680 participants took the drug for an extended period, and researchers tracked any side effects. The goal was to see if the medicine is…

This study looked at the safety of a new drug called SEP-363856 for people with schizophrenia who switched from their usual antipsychotic medication. About 75 adults who completed a prior study took the new drug for up to 25 weeks. Researchers tracked side effects to see if the d…

This study tested a new drug, centanafadine, for adults with major depression who hadn't responded well to at least one prior treatment. 337 people took either the new drug alone, the new drug plus a standard antidepressant, or a placebo. The goal was to see if centanafadine coul…

This study tested whether aripiprazole, a medication, could reduce serious behavioral issues like irritability and agitation in children and teens (ages 6-17) with autism. Participants received either the drug or a placebo for 8 weeks. The goal was to see if the drug improved beh…

This study tested an experimental drug called AVP-786 in 145 people with schizophrenia whose symptoms were not fully controlled by their current medication. The goal was to see if adding AVP-786 could reduce negative symptoms like lack of motivation and social withdrawal. Partici…

This study tested a once-daily pill called centanafadine in 315 adults aged 18 to 65 who have both ADHD and anxiety (generalized or social anxiety). For 8 weeks, participants received either the drug or a placebo to see if it reduces ADHD symptoms and anxiety. The goal is to find…

This early-stage study tested an oral medication called brexpiprazole in 43 teenagers aged 13 to 17 with schizophrenia or related disorders. The main goal was to check the drug's safety and how the body processes it, not to measure how well it works. Researchers monitored side ef…

This study tested a new medication called SEP-363856 in 434 adults with Generalized Anxiety Disorder. Participants took the drug or a placebo for up to 12 weeks to see if it reduces anxiety symptoms. The goal is to find a safe and effective treatment option.

This study tested a new drug called SEP-363856 in 929 adults with major depression who had not gotten better with at least one antidepressant. Participants took either the new drug or a placebo alongside their current antidepressant for several weeks. The goal was to see if the n…

This study tested whether aripiprazole, a medication, can reduce serious behavioral problems like irritability and agitation in children and adolescents (ages 6-17) with autistic disorder. 218 participants received either a fixed dose of aripiprazole or a placebo for 8 weeks. The…

This study tested a once-daily medication called centanafadine in 574 children aged 4 to 12 with ADHD. The goal was to see if it reduces ADHD symptoms better than a placebo over 6 weeks. Researchers measured changes in symptom scores and overall severity to determine effectivenes…

This study tested an experimental drug called AVP-786 to see if it could reduce aggression, agitation, and irritability in people who had a traumatic brain injury (TBI). The trial included 168 participants and compared the drug to a placebo. The goal was to find a safe and effect…

This study tested a new drug, CAN10, for the first time in humans. It aimed to see if the drug is safe and how the body handles it. The trial included 80 healthy adults and people with mild to moderate plaque psoriasis. The drug was given as a single dose to healthy volunteers an…

This study tested a new medication called EB-1020 SR (centanafadine) in 45 adult men with ADHD. The goal was to see if it could reduce ADHD symptoms like inattention and hyperactivity. Participants took the drug for 4 weeks, and researchers measured changes using a standard ADHD …

This study tested a new medication called centanafadine in 147 adults with moderate to severe binge eating disorder. Participants took either a low dose, a high dose, or a placebo pill daily for several weeks. The main goal was to see if the drug could reduce the number of days p…

This study looked at whether the experimental drug EB-1020 could be abused, like other stimulants. It involved 80 healthy adults who occasionally use stimulants for fun. Researchers gave them single doses of EB-1020, a placebo (dummy pill), or d-amphetamine (a known stimulant) an…

This early-stage study tested a new drug called VIS649 in healthy adults to see if it is safe and how the body processes it. The drug is designed to target a protein linked to IgA nephropathy, a kidney disease. 51 healthy volunteers received either the drug or a placebo. This stu…

This study looked at how a single dose of a radioactive drug called OPC-167832 leaves the body. Eight healthy men took the drug, and researchers measured how much came out in their urine and stool. The goal was simply to understand the drug's journey, not to treat any disease.

This early-stage study tested a new drug called EB-1020 in 54 healthy adults aged 18-45. The main goals were to see if taking the drug with food changes how the body absorbs it, and to check the drug's safety and tolerability at different doses. Participants received the drug in …

This early-phase study tested the safety and how the body processes AVP-786 in 48 healthy adult men aged 18-45. Participants received single or multiple doses of the drug or a placebo. The goal was to measure drug levels in the blood and check for side effects, not to treat any d…

This study involved 44 healthy adults to see if taking two 164.4 mg capsules of centanafadine once daily is equivalent to taking one 328.8 mg capsule. The goal was to measure drug levels in the blood, not to treat any disease. Participants were in good health and received both do…

This study looked at how a drug called quinidine changes the way the body processes SEP-380135, a potential schizophrenia treatment. Twelve healthy adults took a single dose of SEP-380135 with and without quinidine to measure drug levels and safety. The goal was to understand pos…

This study tested a new drug, VIS954, in 54 healthy adults to see if it is safe and how the body processes it. Participants received either the drug or a placebo, and researchers monitored for side effects. Since this was a first-in-human trial, the goal was only to gather safety…

This study looked at how two similar drugs, AVP-786 and AVP-923, are processed by the body. 62 healthy adults took both drugs at different times. The goal was to measure drug levels and check safety, not to treat any disease.

This early-stage study looked at how a common antifungal drug, itraconazole, changes the levels of two experimental drugs (AVP-923 and AVP-786) in the blood. Twenty-four healthy adults took part to help researchers understand potential drug interactions and safety. The goal was t…

This study tested different versions of a drug called centanafadine, which is being developed for ADHD. 174 healthy adults took the drug in various capsule and tablet forms to see how well the body absorbs each version and whether food changes absorption. The goal was to compare …

This completed phase 1 study looked at how centanafadine, a potential ADHD treatment, affects the body when taken with common stimulant medicines like methylphenidate or lisdexamfetamine. Forty healthy adults participated to measure changes in blood pressure, heart rate, and drug…

This study looked at how healthy men take in, break down, and get rid of a drug called JNT-517. Eight participants each took one dose, and researchers measured the drug and its byproducts in blood, urine, and stool. The goal was not to treat any disease, but to understand how the…

This early-stage study tested a new oral drug, SEP-380135, in 43 adults with schizophrenia or major depression (including bipolar disorder). The main goal was to check if the drug is safe and how the body processes it. Researchers measured side effects, vital signs, and mood chan…

This study followed over 3,400 people with ADPKD, a genetic condition that causes cysts to grow in the kidneys. Researchers measured kidney size and other health changes over time to better understand how the disease progresses. The goal was to identify which patients are at high…

This early-stage study tested a new drug called AVP-786 in 56 healthy adult men to see how the body processes it and whether it is safe. Participants took the drug and were monitored for side effects and drug levels in the blood. The study did not aim to treat any disease, but to…

This study looked at how two different versions of the drug centanafadine are absorbed by the body. 62 healthy adults took either a sustained-release tablet or a once-daily extended-release capsule. The goal was to see which form delivers the drug more effectively, which can help…

This study looked at how a new tuberculosis drug, OPC-167832, interacts with other medicines in 24 healthy adults. Participants took the drug alone and with either a common antifungal or seizure medication to see how their bodies processed it. The goal was to check for safety and…